| | | | | | | | | | | | | | | | |
| |
 | Issue Date FY: 2022 ( Subtotal = $13,964,503 ) (Continued on the next page) |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 011 | 55 | NIH | 5/13/2022 | $400,000 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA262551 | Folic Acid Supplementation and Colitis-associated Colon Carcinogenesis | 000 | 1 | NIH | 5/11/2022 | $423,946 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R03CA273479 | Pancreatic adenocarcinoma secretome as a dynamic biomarker for patient stromal reprogramming efficacy | 000 | 1 | NIH | 7/11/2022 | $94,000 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R21CA263362 | Tumor-specific anti-angiogenic anti-CD70-FGF/VEGF-trap fusion antibodies for renal cancer therapy | 000 | 1 | NIH | 4/11/2022 | $219,725 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA262466 | Assessing DNA polymerase theta as a therapeutic target in BRCA1 mutant cancer | 000 | 1 | NIH | 2/24/2022 | $427,763 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA262466 | Assessing DNA polymerase theta as a therapeutic target in BRCA1 mutant cancer | 001 | 1 | NIH | 2/25/2022 | $2,287 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R21AI168799 | Necroptosis in SARS-CoV-2 pathogenesis, evolution, and therapy | 000 | 1 | NIH | 1/28/2022 | $280,000 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01GM141513 | Designing selective kinase inhibitors via deep learning | 000 | 1 | NIH | 1/18/2022 | $549,557 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R35GM119560 | Novel Regulatory Mechanisms Underlying Inside-out Integrin Activation | 002 | 6 | NIH | 7/15/2022 | $69,354 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R35GM119560 | Novel Regulatory Mechanisms Underlying Inside-out Integrin Activation | 001 | 6 | NIH | 12/13/2021 | $481,525 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA269660 | Pancreatic cancer-associated fibroblasts: function, detection, and regulation | 000 | 1 | NIH | 5/20/2022 | $517,107 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R21AI157375 | Characterization of New Allosteric Inhibitors that Disrupt HIV-1 Integrase Dimerization | 000 | 2 | NIH | 11/9/2021 | $233,750 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R00ES031148 | Repair of Oxidative Damage in G-Quadruplex Promoter DNA | 001 | 3 | NIH | 4/27/2022 | $0 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R00ES031148 | Repair of Oxidative Damage in G-Quadruplex Promoter DNA | 000 | 3 | NIH | 3/3/2022 | $249,000 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R25CA259244 | Empowering the Next Generation of Cancer Professionals: the Fox Chase Cancer Center-University of Delaware Partnership for Undergraduate Research and Career Development | 000 | 1 | NIH | 3/11/2022 | $215,169 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R35GM144131 | Deciphering Networks Controlling DNA Amplification | 000 | 1 | NIH | 12/23/2021 | $467,500 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R21CA263415 | Building clinically faithful ex vivo indolent lymphoma models for personalized therapy | 000 | 2 | NIH | 7/6/2022 | $214,186 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R21CA252535 | Neoadjuvant Stroma Modification in Pancreatic Cancer | 000 | 2 | NIH | 8/3/2022 | $249,135 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA251674 | Analysis and Therapeutic Targeting of the Linear-Ubiquitination Pathway in Hodgkin Lymphoma | 000 | 2 | NIH | 5/16/2022 | $427,763 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA259188 | Investigating the IL-1R Pathway in Anaplastic Large Cell Lymphoma for Targeted Therapy | 000 | 2 | NIH | 3/30/2022 | $407,062 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R21HD105295 | Neurotransmitter signaling controls stem cell fate | 000 | 2 | NIH | 4/23/2022 | $233,750 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | U01CA260369 | Optimization of urinary DNA deep sequencing tests to enhance clinical staging of bladder cancer patients | 000 | 2 | NIH | 8/1/2022 | $414,249 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R03CA256762 | Identification of first-in-class epigenetic inhibitors that target Thymine DNA Glycosylase (TDG) for future precision therapy of metastatic melanoma | 000 | 2 | NIH | 12/2/2021 | $93,500 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA245871 | MTAP, 5'-deoxy-5'-methylthioadenosine, and the dysregulation of symmetric dimethylarginine in cancer | 000 | 3 | NIH | 4/27/2022 | $419,207 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R37AI110985 | Regulation of hematopoiesis by ribosomal protein paralogs | 000 | 8 | NIH | 1/10/2022 | $561,000 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R03CA256234 | Comprehensive identification of RAS mutations and allelic co-segregation patterns in colorectal cancer | 000 | 2 | NIH | 11/16/2021 | $93,500 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01GM135293 | Dissecting BRCA1-PALB2 Activity in DNA Repair and Development | 000 | 3 | NIH | 7/13/2022 | $408,313 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01HL150190 | The role of microhomology-mediated end joining in Fanconi anemia pathogenesis | 001 | 3 | NIH | 6/15/2022 | $45,409 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01HL150190 | The role of microhomology-mediated end joining in Fanconi anemia pathogenesis | 000 | 3 | NIH | 2/25/2022 | $408,681 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA248655 | Evidence-Based Approach to Empower Asian American Women in Cervical Cancer Screening | 001 | 3 | NIH | 6/14/2022 | $50,316 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA248655 | Evidence-Based Approach to Empower Asian American Women in Cervical Cancer Screening | 000 | 3 | NIH | 3/11/2022 | $566,049 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA236391 | Novel Role of ThPOK in Mammary Carcinoma | 001 | 4 | NIH | 4/25/2022 | $50,831 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA236391 | Novel Role of ThPOK in Mammary Carcinoma | 000 | 4 | NIH | 3/22/2022 | $571,833 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA238061 | Investigating genetic ancestry influences on oral cavity and laryngeal cancer survival disparities | 000 | 4 | NIH | 4/11/2022 | $578,891 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01MD013347 | Extending a Caribbean Based Cohort to Promote US-Caribbean Comparisons to Facilitate Research Addressing Black Health Disparities | 002 | 5 | NIH | 6/30/2022 | $0 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01MD013347 | Extending a Caribbean Based Cohort to Promote US-Caribbean Comparisons to Facilitate Research Addressing Black Health Disparities | 001 | 5 | NIH | 4/26/2022 | $67,061 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01MD013347 | Extending a Caribbean Based Cohort to Promote US-Caribbean Comparisons to Facilitate Research Addressing Black Health Disparities | 000 | 5 | NIH | 3/23/2022 | $603,522 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01MD012621 | Immigrant enclaves: Conferring health advantages or creating health disparities in Chinese immigrants? | 000 | 5 | NIH | 12/16/2021 | $768,973 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01MD012621 | Immigrant enclaves: Conferring health advantages or creating health disparities in Chinese immigrants? | 001 | 5 | NIH | 4/17/2022 | $85,441 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA217161 | Lung Cancer in Never-smokers: Role of Estrogen and its Metabolites | 003 | 5 | NIH | 4/25/2022 | $14,640 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA217161 | Lung Cancer in Never-smokers: Role of Estrogen and its Metabolites | 002 | 5 | NIH | 4/25/2022 | -$130,496 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA217161 | Lung Cancer in Never-smokers: Role of Estrogen and its Metabolites | 000 | 5 | NIH | 2/25/2022 | $549,703 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA217161 | Lung Cancer in Never-smokers: Role of Estrogen and its Metabolites | 001 | 5 | NIH | 3/3/2022 | $164,719 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01AI135025 | Mechanism, Function, and Exploitation of Influenza A Virus-Activated Cell Death | 000 | 6 | NIH | 4/15/2022 | $742,326 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01GM102503 | The Role of Histone Chaperones in Histone Acetylation and Nucleosome Dynamics | 000 | 8 | NIH | 6/9/2022 | $498,606 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 016 | 55 | NIH | 8/2/2022 | $0 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 017 | 55 | NIH | 8/3/2022 | $0 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | UH2CA271230 | Validation of blood-based predictive biomarkers of therapeutic response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer | 000 | 1 | NIH | 4/29/2022 | $258,829 |
| 2022 | 2022 | INSTITUTE FOR CANCER RESEARCH, THE | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 010 | 55 | NIH | 5/12/2022 | $250,000 |
|